Diligence memo · auto-generated · as of July 2, 2026

AskY Therapeutics, Inc.

AskY Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.

SourceRaising on rhythm with a 1.6× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

AskY Therapeutics, Inc. operates in Biotechnology, based in Owings Mills.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

AskY Therapeutics, Inc. has raised $740K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $460K on 2024-05-21.

Most recent recorded round closed around 2024-05-21.

Valuation (modeled)modeled

Provath models AskY Therapeutics, Inc. at approximately $2.3M (range $245K–$7.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.71× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 18 months.

Last raise 2.1 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round stepped up 1.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 14% of Biotechnology peers (4293 compared).

Modeled value ranks above 6% of those peers.

Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.